Cover Image


View/Hide Left Panel

TABLE B Summary of Adverse Effects in Clinical Trials Using Saw Palmetto in Blended Preparations

Study Design


Parameters Monitored

Supplement / Placebo / Reference

Adverse Effects and Related Findings

Clinical Trial Using Blended Preparations with Female Subjects

1 trial, 20 subjects ingested blended saw palmetto-containing preparations, 10 subjects in placebo group

Timmermans and Timmermans, 1990




Condition: Hypotonic bladder [incontinence (18 subjects) and other conditions]

Age: 25-76 y

All subjects were female.

Parameters monitored: Unknown

Saw palmetto group:

Number of subjects: 20 (25–68 y, mean age of 45y)

Type: Extract of saw palmetto fruit plus extract of Echinacea purpurea in dropsa

Amount: 78-104 mg/day (90-120 drops/day)

Route: Oral

Frequency: ~3 times/day (20–25 drops/dose) Duration: ~ 77 days (mean)

Saw palmetto group:

Adverse effects: Unknown




Placebo group:

Number of subjects: 10 (29–76 y, mean age of 52 y) Form: Drops Duration: ~52 days (mean)

Placebo group:

Adverse effects: Unknown

a Urgenin® (Madaus GmbH, Wien, Austria) contained an extract/tincture of saw palmetto fruit (78-104 mg/day) and an extract of rhizomes/roots of purple coneflower (Echinacea purpurea) (84-112 mg/day). This product was a liquid intended for use as drops (~25 drops) to be ingested in water before meals (or after meals in subjects with gastric disturbances). Urgenin was used in the one clinical trial with female subjects summarized in this table.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement